L'intérêt à découvert pour Cartesian Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Cartesian Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Cartesian Therapeutics (NASDAQ:RNAC) Stock, Rapport sur les intérêts à découvert

CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

On July 15, 2025, BioXcel Therapeutics, Inc. announced that the United States Patent and Trademark Office had allowed U.S. Patent Application No. 18/600,419 with claims pertaining to the administration of a single dose of up to 120 mcg of dexmedetomidine in an oromucosal formulation for the treatment of acute agitation associated with schizophrenia or bipolar disorder in certain patient subpopulations where the patient exhibits a maximum allowed QT prolongation of less than six microseconds. The allowed claims mirror the recommended IGALMI dosing regime for treatment of patients meeting this QT prolongation criteria. Once issued, this patent will be eligible for listing in the Orange Book for Igalmi and will be the 14th Orange Book listed patent for Igalmi. This patent will have an expiry date of January 12, 2043, subject to patent term adjustment.

Biotech

News

General

BTAI

BioXcel Therapeutics Granted New U.S. Patent For IGALMI Dosing In Acute Agitation, Expanding Protection Through 2043

Former Labor Secretary Robert Reich is calling out the Trump administration over a sweeping deregulatory push at the Department of Labor. Reich says the move strips essential worker protections, even as President Donald Trump continues to brand himself as a champion of the American worker.
<h2 class="wp-block-heading">More Than 60 Rules On The Chopping Block</h2>
Reich <a href="https://x.com/RBReich/status/1942671313149042824">took to X</a> on July 8 to criticize what he called a direct attack on labor rights. "Trump&#8217;s Labor Department is gutting more than 60 regulations," he wrote, listing key protections including &#8220;minimum wage &amp; overtime pay for in-home care workers,&#8221; &#8220;organizing rights for migrant farmworkers,&#8221; and &#8220;penalties for companies that don't maintain a safe workplace.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
He ended the post with a sarcastic jab: "The ‘pro-worker' president strikes again."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump&#39;s Labor Department is gutting more than 60 regulations, including: -Minimum wage &amp; overtime pay for in-home care workers -Organizing rights for migrant farmworkers -Penalties for companies that don't maintain a safe workplace The "pro-worker" president strikes again.
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1942671313149042824?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The deregulation effort is being led by Labor Secretary Lori Chavez-DeRemer, who described the changes as a historic rollback of burdensome rules. "The Department of Labor is proud to lead the way by <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">eliminating unnecessary regulations</a> that stifle growth and limit opportunity,&#8221; she said in a <a href="https://www.dol.gov/newsroom/releases/osec/osec20250701-0">statement</a> on July 1. "These historic actions will free Main Street, fuel economic growth and job creation, and give American workers the flexibility they need to build a better future."
The department is proposing 63 deregulatory actions, including cutting back on diversity, equity and inclusion efforts, removing certain safety rules in mining, and scrapping affirmative outreach requirements for programs that support workers with employment barriers.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Deputy Labor Secretary Keith Sonderling called the move "unprecedented," adding that, "While the previous administration prioritized expanding the size of government over job and wage growth, President Trump is focused on unleashing the greatest economic comeback in American history."
Critics say many of the rules being scrapped were put in place to protect the country's most vulnerable workers. The cuts build on 37 similar actions from Trump's first term and follow a new <a href="https://www.whitehouse.gov/fact-sheets/2025/01/fact-sheet-president-donald-j-trump-launches-massive-10-to-1-deregulation-initiative/">executive order</a> that requires eliminating 10 regulations for every new one issued.
Reich, who served under President Bill Clinton, has long warned that Trump's pro-worker image doesn't match his policies. The latest move, he argues, is more proof.
On the same day, Reich also pointed to the broader consequences of Trump's federal workforce policies: "Trump's <a href="https://www.benzinga.com/news/politics/25/07/46313304/trumps-federal-job-cuts-gets-supreme-court-go-ahead-doge-outpaces-big-tech-in-layoffs-across-us-bureaucracy">firings at federal agencies</a> have upended the lives of thousands of workers," he <a href="https://x.com/RBReich/status/1942693524195184703">wrote</a>. "These are the people who oversee air safety, food and drug safety, disaster response, public health, and much more."
Read Next:
<ul class="wp-block-list">
<li>This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

The 'Pro-Worker' President Strikes Again'—Ex-Labor Secretary Slams Trump's Labor Department For Gutting Over 60 Worker Protections

Trading Ideas

RAPT

RAPT Therapeutics Shares Resume Trade

CYCC

Cyclacel Pharmaceuticals Shares Resume Trade

Macro Economic Events

Global

Economics

Reuters Cites Brazil's Suzano Exec Saying Consumer In North America Will Have To Bear The Additional Cost Stemming From Tariffs

<ul>
<li>The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR &#xAE;, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors</li>
<li>Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030</li>
<li>Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments</li>
<li>Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR&#xAE; platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=achieved+FDA+clearance+for+a+Phase+1B%2F2+clinical+trial+in+triple-negative+breast+cancer+%28TNBC%29&amp;index=1&amp;md5=018505482c93aeed3a9a3d6255d12b3c">achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC)</a>, focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.
In a peer-reviewed study published in Frontiers in Oncology, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.3389%2Ffonc.2025.1577468&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Clinical+outcomes+of+DNA-damaging+agents+and+DNA+damage+response+inhibitors+combinations+in+cancer%3A+a+data-driven+review&amp;index=2&amp;md5=decb84403c612e661b24bdd68f046d29">Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review</a>, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module.1
Transforming Cancer Combination Therapy Development
The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Lantern%27s+FDA-cleared+Phase+1B%2F2+clinical+trial+combining+LP-184+with+olaparib+in+triple-negative+breast+cancer&amp;index=3&amp;md5=944624f8b7c28bae6c8c8c6a7b5026be">Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer</a> (TNBC).

LTRN

Lantern Pharma Launches AI Module Trained On 221 Clinical Trials To Predict Efficacy Of DNA-Damaging Agent Combinations; Platform Already Guided FDA-Cleared Phase 1B/2 Trial In Triple-Negative Breast Cancer

Small Cap Consumer Research analyst Eric Beder reiterates Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on Lands' End, Maintains $20 Price Target

KAPA

Kairos Pharma Shares Resume Trade

RAPT Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29.1%

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 82.5%

RBC Capital analyst Elvira Scotto reiterates Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Outperform and maintains $63 price target.

RBC Capital Reiterates Outperform on Williams Companies, Maintains $63 Price Target

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $85 to $51.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $51

Reuters Cites Brazil's Suzano Exec Saying Brazil Represents 83% Of The Total Hardwood Pulp That U.S. Imports In A Given Year, That's A Relevant Number; Suzano Itself Will Find Ways Of Selling Those Those Products To Other Markets; But The Best Outcome Obviously Is Keeping The Relationships We Have Established For Several Years In North America; It's Very Hard To Predict From Our Side What Will Come, The The Lack Of Visibility Of The Next Steps Is A Factor

RBC Capital analyst Elvira Scotto reiterates Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and maintains $205 price target.

TRGP

RBC Capital Reiterates Outperform on Targa Resources, Maintains $205 Price Target

Oppenheimer analyst Tyler Batory maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and raises the price target from $125 to $132.

Oppenheimer Maintains Outperform on PulteGroup, Raises Price Target to $132

Kairos Pharma Shares Halted On Circuit Breaker To The Downside, Stock Now Up 124.8%

Mizuho analyst John Roberts maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Outperform and raises the price target from $52 to $59.

Mizuho Maintains Outperform on Corning, Raises Price Target to $59

RBC Capital analyst Scott Hanold reiterates Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Sector Perform and maintains $45 price target.

RBC Capital Reiterates Sector Perform on Range Resources, Maintains $45 Price Target

Mizuho analyst John Roberts maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Outperform and raises the price target from $24 to $27.

Mizuho Maintains Outperform on Element Solutions, Raises Price Target to $27

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 55.3%

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Earnings

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Comments

Cartesian Therapeutics

Intérêt court

Cartesian Therapeutics (NASDAQ:RNAC) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL